What is Northland Securities' Estimate for CHRN Q2 Earnings?

Key Points

• Northland Securities estimates Q2 2026 earnings of a loss of $0.08 per share for CHRN and maintains an “Outperform” rating with a $32 price target. Full-year consensus earnings are estimated at a loss of $0.10 per share.
• Analyst sentiment is mixed, with one Buy, one Hold, and one Sell rating; the overall consensus is “Hold” with a $19 average price target.
• CHRN shares recently rose 6.2% to $21.69. The company’s latest quarter showed a $0.12-per-share loss on $18.4 million in revenue.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Free Report) - Analysts at Northland Securities issued their Q2 2026 earnings estimates for ChronoScale Corporation Common Stock in a research report issued to clients and investors on Friday, September 18th. Northland Securities analyst N. Chokshi expects that the company will earn ($0.08) per share for the quarter. Northland Securities has a "Outperform" rating and a $32.00 price objective on the stock. The consensus estimate for ChronoScale Corporation Common Stock's current full-year earnings is ($0.10) per share.

Separately, Weiss Ratings raised shares of ChronoScale Corporation Common Stock from a "sell (d-)" rating to a "sell (d)" rating in a report on Monday, August 24th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $19.00.

ChronoScale Corporation Common Stock Stock Up 6.2%

Shares of NASDAQ:CHRN opened at $21.69 on Tuesday. The business's 50 day moving average is $21.52 and its 200 day moving average is $17.19. ChronoScale Corporation Common Stock has a 12-month low of $3.50 and a 12-month high of $30.00. The stock has a market cap of $3.16 billion, a price-to-earnings ratio of -4.03 and a beta of 0.98. The company has a quick ratio of 0.51, a current ratio of 0.51 and a debt-to-equity ratio of 0.06.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) last posted its earnings results on Wednesday, August 19th. The company reported ($0.12) earnings per share for the quarter. The business had revenue of $18.40 million during the quarter. ChronoScale Corporation Common Stock had a negative return on equity of 197.81% and a negative net margin of 135.66%.

Institutional Investors Weigh In On ChronoScale Corporation Common Stock

A hedge fund recently raised its stake in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc raised its holdings in ChronoScale Corporation Common Stock (NASDAQ:CHRN - Free Report) by 104.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,338 shares of the company's stock after purchasing an additional 1,195 shares during the period. Roble Belko & Company Inc owned 0.07% of ChronoScale Corporation Common Stock worth $25,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.42% of the company's stock.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.